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Clinicians are often faced with 2 important issues when
treating patients with peripheral arterial disease (PAD) and
coronary artery disease (CAD): 1) reduction of cardiovas-
cular risk and 2) improvement of symptoms. Although
multiple therapies (antiplatelet agents, statins, antihyperten-
sive agents) have been proven to reduce cardiovascular risk
in both CAD and PAD patients, unlike CAD, very few
therapeutic agents have been shown to improve leg symp-
toms in PAD patients. Statins are currently listed as a Class
IB recommendation in the PAD guidelines with specific
recommendations about low-density lipoprotein (LDL)
goals, but no recommendation about their use for symptom
management (1). The current guideline-based approach for
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PAD patients with intermittent claudication is to recom-
mend aerobic exercise training and cilostazol, a phosphodi-
esterase inhibitor that has been shown to improve walking
performance (1). If symptoms do not improve with these
measures, patients may be referred for angiography and
consideration for endovascular or surgical revascularization
for lifestyle-limiting symptoms. Despite these therapies,
there is a large unmet need and corresponding knowledge
gap in terms of leg-specific therapies that lead to improved
long-term walking performance and functional capacity.
Similar to angina in CAD patients, the mechanism of
functional improvement in PAD patients most often tar-
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paper to disclose.geted has been the macrovasculature, either through plaque
stabilization or regression or vasodilatory effects. Despite a
lack of previous evidence demonstrating an improvement in
angina in CAD patients with statin therapy, many investi-
gators have studied the effect of statins on leg symptoms in
PAD. Two previous studies reported that high-dose statin
therapy was associated with improved pain-free walking
time, but the effects on maximal walking time were incon-
gruent (2,3). Another observational study reported that
statins were associated with improved walking velocity and
6-min walking distance (4). Considerable debate remains
about the association of statins with improved functional
outcomes and the proposed mechanism of improvement.
In this issue of the Journal, West et al. (5) tested the
hypothesis that LDL reduction would improve calf muscle
perfusion, metabolism, and walking performance in PAD
patients. In the 68 patients randomized to simvastatin, a
combination of simvastatin and ezetemibe, or ezetemibe
added to an already existing statin medication, there was no
change in calf muscle perfusion as detected by magnetic
resonance imaging (MRI), calf muscle metabolism as de-
tected by magnetic resonance spectroscopy (MRS), or walk-
ing performance. It should be noted that all groups were on
guideline-recommended statin therapy, and therefore the
effects of statin therapy versus placebo cannot be ascertained
from the current study. These findings build logically on
previous work by this group that has focused on noninvasive
imaging and calf muscle perfusion in PAD (6–10). Al-
though the study essentially fails to show a significant
difference in functional outcomes, the results add to mech-
anistic observations on the effects of statins. With the
limited number of patients studied, the conclusiveness of
these observations or their association with functional out-
comes in PAD patients remains speculative.
The study’s largely negative endpoints thus still leave
several unanswered questions about both the role of medical
therapies affecting lipid metabolism and the mechanistic
assumptions underlying the role of such therapies in PAD
patients. Three such questions include: 1) the causality of
plaque regression and improved clinical outcomes; 2) the
potential adjunctive use of statins and mechanical revascu-
larization with peripheral vascular intervention (PVI) in
PAD patients; and 3) the optimal measurement and end-
points of functional capacity in PAD. The first question can
be put into context by reviewing the findings of statin trials
in patients with atherosclerosis in other vascular beds. It is
now accepted that patients with atherosclerosis have im-
proved clinical outcomes with statins, particularly with high
doses of selected statins (11,12). Studies from the coronary
and carotid vasculature have documented atherosclerotic
plaque stabilization and even plaque regression with statins.
In addition to plaque stabilization/regression, the improve-
ment in clinical outcomes with statins has been hypothe-
sized to be caused by a reduction in LDL levels, a reduction
in systemic inflammation, and other pleiotropic effects
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cular ultrasound (IVUS) study in the coronary literature
(REVERSAL [REVERSing Atherosclerosis with Aggres-
sive Lipid Lowering]) showed that in patients treated with
high-dose atorvastatin, there was no change in atheroma
burden, whereas those treated with pravastatin had a pro-
gression in atheroma burden (13). A similar coronary IVUS
trial (ASTEROID [A Study To Evaluate the Effect of
Rosuvastatin on Intravascular Ultrasound-Derived Coro-
nary Atheroma Burden]) showed that in patients treated
with 40 mg of rosuvastatin, there was a significant regres-
sion in atheroma burden (14). Although statin trials have
now shown that plaque regression is possible and that
clinical outcomes are improved, there has never been a
correlation between plaque regression and improved angina
or other functional outcomes (15). Moreover, the degree of
plaque regression noted in the coronary trials may not be
clinically significant in the large-vessel lower extremity
vascular bed. The current study further weakens this link in
PAD patients, and the authors suggest that targeting the
microvasculature or skeletal muscle may be more important.
They also importantly recognize that although PAD symp-
toms did not get better, functional status did not worsen,
which is a potentially important and positive observation
outside of the study’s primary analysis plan, but comple-
mented by the 2-year follow-up in most of the study
patients enrolled.
Another potential benefit of statin therapy is in conjunc-
tion with mechanical revascularization. Acute statin therapy
has been shown to potentially mitigate and/or reduce
adverse events at the time of percutaneous coronary
intervention (16). In the coronary bed, statin therapy may
contribute to reduction of periprocedural myonecrosis,
although such drug–device interactions are complex to
establish. Unlike the coronary bed, the vasculature of the
lower extremities is different in that it serves skeletal
muscle and generally involves larger reference vessels at
the point of intervention, and long-term adverse out-
comes may be driven more by the overall burden of
disease than by local events such as plaque rupture. These
issues further highlight the need for specific studies
targeting the effects of medical strategies such as statins
in patients with PAD.
Taken together, the results of the current study suggest
that plaque regression is only 1 endpoint within a myriad of
potential responses to the medical, or overall, treatment of
patients with atherosclerosis. As stated, PAD represents a
complex and heterogeneous disease with multiple vascular
beds and physiological mechanisms for symptomatic pro-
gression and adverse outcomes. This complexity itself must
be considered in study designs, especially in the selection of
surrogate/mechanistic endpoint measures, and in the inter-
pretation of study results as the basis by which clinicians
make therapeutic decisions to treat PAD patients most
effectively. The authors should be commended for continu-
ing to investigate and understand the mechanisms of diseaseand therapeutics in patients with PAD. Unfortunately, this
also points to the enormous gap between how informative
small studies can be and the many questions that remain to
define optimal therapy in clinical practice, because even the
definition of key patient subgroups by clinical presentation,
macro- and microvascular anatomy, and physiology impor-
tantly intersect in real-world practice. Selection and timing
of medical regimens, mechanical revascularization, and
exercise prescription are still relegated to selection based
more on experience and judgment than on definable, data-
driven practice. To move the light of knowledge forward in
this enormous arena of human suffering, clear and careful
distinctions must be maintained between both tools and
statistical analyses directed to mechanistic effects, symp-
toms, functional capacity, and clinical outcomes in either
the relief from or the progression of PAD.
So, specifically, how can the field of PAD research move
forward along these lines? Much like therapeutic develop-
ment in patients with CAD, only large observational regis-
tries and randomized trials will be able to provide informa-
tion linking measured surrogate physiological markers such
as ankle-brachial index, transcutaneous oxygen, and tissues
perfusion by cardiac magnetic resonance to functional and
clinical outcomes such as walking time, cardiovascular
death, myocardial infarction, and amputation. The pace at
which such changes may occur also mandate both measure-
ments and follow-up over both the short and long term.
These features are not only true of key benefits related to
therapies targeting PAD, but also imperative to information
about safety and relative cost-effectiveness.
Underlying the overall utility of all PAD studies is a
critical lesson learned about the value of information in
complex areas that is being collected using consensus
definitions that have pragmatic constructs supporting essen-
tial aspects of high-quality therapeutic trials, such as inde-
pendent event adjudication and consistent core laboratory
reporting. Examples of such definitions have been devel-
oped across academic, regulatory, and industry experts in the
Academic Research Consortium and disseminated into the
public domain through peer-reviewed publication for coro-
nary stent studies (17), percutaneous aortic valve interven-
tion (18), and bleeding events (19). Although no single
definition may be perfectly sensitive and specific per se for
any entity, the use of consensus definitions across study
reports in developing areas supports more robust opportu-
nities for data pooling and hence uniquely promotes the
leveraged advance of knowledge in ways that individual
studies using individualized definitions cannot.
For PAD therapeutics, there is a clear need to develop
consensus definitions of symptom status, anatomy, objective
physiological measures, patient-reported outcomes, and key
clinical outcomes. In developing such a consensus dictionary
of nomenclature, work already done or in progress for
clinical practice guidelines or other more generic areas
(such as bleeding) should be incorporated as much as
possible because both clinical trials and practice guide-
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another. As reflected by the conundrum of how exactly to
interpret the study reported by West et al. (5), now is the
time for an international effort to establish such consen-
sus because the field of PAD medical, mechanical, and
overall optimal vascular therapies is poised to advance
against the functional and clinical incapacity that PAD
inflicts on patients around the world.
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